Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sound waves aimed at liver and nerves could tame diabetes

NCT ID NCT05354947

First seen Feb 02, 2026 · Last updated Jun 23, 2026 · Updated 22 times

Summary

This early study tests whether delivering focused ultrasound pulses to the liver and a nearby nerve bundle can improve blood sugar control in people with type 2 diabetes. Thirty adults on stable oral diabetes medications will receive the ultrasound treatment. The main goal is to check for side effects like liver enzyme changes, but researchers will also monitor blood sugar levels to see if the approach shows promise.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Yale-New Haven Hospital

    RECRUITING

    New Haven, Connecticut, 06510, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

focused pulsed ultrasound delivered via a GE LOGIQ E10 machine

What this could lead to

If it works, this could point toward a non-drug, non-invasive way to help manage blood sugar in type 2 diabetes.

What could go wrong

This is a very early, small pilot study (30 people) focused on safety, not effectiveness. It may not show any meaningful blood sugar improvement, and there is a risk of liver enzyme elevation or low blood sugar.

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.